Fasting hyperglycemia contributes disproportionately to nonenzymatic glycosylation and the microvascular complications of type 2 diabetes. However, little is known about the regulation of glucose concentrations in the fasting state relative to what is known about the postprandial state. The proposed experiment is part of a series of experiments designed to establish how glucagon and insulin interact with their receptors to control fasting glucose in health and in prediabetes.

Start Date01 Sep 2024

Sponsor / Collaborator

Mayo Clinic

CTRI/2024/08/072588 / Not yet recruitingNot Applicable

Heparin Dose Response Curve for Heparin Dose Determination During Paediatric Cardiopulmonary Bypass for Cardiac Surgery: A Prospective Randomised Control Study - Nil

Start Date25 Aug 2024

Sponsor / Collaborator-

CTRI/2024/07/071587 / Not yet recruitingNot ApplicableIIT

Comparative Evaluation Of Umbilical Cord Blood Serum Versus Low Dose Heparin Drops Versus Amniotic Membrane Grafting For Ocular Manifestations In Acute Stevens-Johnson Syndrome - nil

Start Date16 Aug 2024

Sponsor / Collaborator-

100 Clinical Results associated with Heparin Calcium

100 Translational Medicine associated with Heparin Calcium

100 Patents (Medical) associated with Heparin Calcium

63,319

Literatures (Medical) associated with Heparin Calcium

01 Apr 2025·DEN Open

Establishment of a swine model of delayed bleeding after endoscopic procedure

Article

Author: Tanaka, Akihito ; Arima, Shiho ; Maeda, Hidehito ; Ido, Akio ; Hinokuchi, Makoto ; Sahara, Hisashi ; Uehara, Shohei ; Sasaki, Fumisato ; Kanmura, Shuji ; Hashimoto, Shinichi

AbstractObjectivesAlthough delayed bleeding after endoscopic procedures has become a problem, currently, there are no appropriate animal models to validate methods for preventing it. This study aimed to establish an animal model of delayed bleeding after endoscopic procedures of the gastrointestinal tract.MethodsActivated coagulation time (ACT) was measured using blood samples drawn from a catheter inserted into the external jugular vein of swine (n = 7; age, 6 months; mean weight, 13.8 kg) under general anesthesia using the cut‐down method. An upper gastrointestinal endoscope was inserted orally, and 12 mucosal defects were created in the stomach by endoscopic mucosal resection using a ligating device. Hemostasis was confirmed at this time point. The heparin group (n = 4) received 50 units/kg of unfractionated heparin via a catheter; after confirming that the ACT was ≥200 s 10 min later, continuous heparin administration (50 units/kg/h) was started. After 24 h, an endoscope was inserted under general anesthesia to evaluate the blood volume in the stomach and the degree of blood adherence at the site of the mucosal defect.ResultsDelayed bleeding was observed in three swine (75%) in the heparin‐treated group, who had a maximum ACT of >220 s before the start of continuous heparin administration. In the non‐treated group (n = 3), no prolonged ACT or delayed bleeding was observed at 24 h.ConclusionAn animal model of delayed bleeding after an endoscopic procedure in the gastrointestinal tract was established using a single dose of heparin and continuous heparin administration after confirming an ACT of 220 s.

31 Dec 2024·Renal Failure

Comparison of citrate dialysate in pre- and post-dilution online hemodiafiltration: effect on clot formation and adequacy of dialysis in hemodialysis patients

Article

Author: Jitraree, Arisara ; Nakornchai, Pasu ; Laykhram, Thanachit ; Trakarnvanich, Thananda ; Homjan, Monpinya Charttong

BACKGROUNDCitrate dialysate (CD) has been successfully used in conventional hemodialysis and continuous renal replacement therapy; however, no study has compared pre- and post-dilution online hemodiafiltration (oL-HDF). Therefore, we aimed to investigate the efficacy of citrate anticoagulation for oL-HDF and the metabolic changes and quality of life of patients on hemodialysis treated using both modes.METHODEight dialysis patients were treated with CD containing 0.8 mmol of citric acid for 4 weeks in each phase. Visual clotting scores were investigated as the primary endpoints. Adequacy of dialysis, laboratory parameters, and quality of life were measured as secondary objectives.RESULTSThe mean clotting scores in the pre-dilution mode were significantly lower than those in the post-dilution mode and in all phases except the heparin-free phase (p < 0.001 in the baseline phase, p = 0.001 in phase 1, and p = 0.023 in phase 2). The values of Kt/V in both modalities were comparable except during the baseline phase, in which the values of pre-dilution were significantly greater than post-dilution (2.36 ± 0.52/week vs. 1.87 ± 0.33/week;95% CI -0.81 to -0.19, p = 0.002). The patient's quality of life regarding their physical activity level was significantly higher in the post-dilution mode than in the pre-dilution mode at baseline and in phase 1 (p = 0.014 and 0.004 at baseline and in phase 1, respectively). Metabolic changes did not differ between the two modes.CONCLUSIONCitrate dialysate decreased or prevented anticoagulation in both pre- and post-dilution modes of oL-HDF without significant side effects and had comparable adequacy of dialysis.

31 Dec 2024·Journal of Pharmaceutical Policy and Practice

Direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer-associated venous thrombosis: a cost-effectiveness analysis

Article

Author: Yiu, Hei Hang Edmund ; Lam, Ka On ; Peng, Kuan ; Ye, Xuxiao ; Wong, Ian C K ; Chan, Esther W ; Li, Silvia T H ; Yan, Vincent K C ; Lee, Victor H F ; Wei, Yue ; Lee, Shing Fung ; El Helali, Aya ; Kang, Wei ; Al-Badriyeh, Daoud

BackgroundDirect oral anticoagulants (DOACs) have demonstrated clinical benefits and better patient adherence over low-molecular-weight heparin (LMWH) in treating patients with cancer-associated venous thrombosis (CAT). We aimed to compare the cost-effectiveness of DOACs against LMWH in patients with CAT from the perspective of the Hong Kong healthcare system.MethodsA Markov state-transition model was performed to estimate the incremental cost-effectiveness ratio (ICER) per quality-adjusted life years (QALYs) for DOACs and LMWH in a hypothetical cohort of 10,000 patients with CAT over a 5-year lifetime horizon. The model was primarily based on the health states of no event, recurrent venous thromboembolism, bleeding, and death. Transition probabilities, relative risks, and utilities were derived from the literature. Resource cost data were obtained from the Hong Kong Hospital Authority. Deterministic and probabilistic sensitivity analyses tested the robustness of the results.ResultsRelative to LMWH, DOACs were associated with increased QALYs (1.52 versus 1.50) at a lower medical cost of USD 2,232 versus 8,224 in five years. The cost of LMWH was the main contributor to the outcome. Out of 10,000 simulated cases, DOACs were dominant in 15.8% and cost-effective in 42.1%, at the willingness-to-pay threshold of USD 148,392 per additional QALY.ConclusionsDOACs were associated with greater QALY improvements and lower overall costs compared to LMWH. Accounting for uncertainty, DOACs were between cost-effective and dominant in 57.9% of cases. DOACs are a cost-effective alternative to LMWH in the management of CAT in Hong Kong.

140

News (Medical) associated with Heparin Calcium

04 Sep 2024

·www.prnewswire.com

Global Heparin Market to Reach ~USD 15 Billion by 2030 | DelveInsight

The demand for heparin is mainly increasing due to the growing incidence of cardiovascular diseases, the expanding range of cancer risk factors such as smoking, radiation exposure, unhealthy lifestyles, and other factors, as well as the rising research and development activities by global market players throughout the forecast period from 2024 to 2030. LAS VEGAS, Sept. 4, 2024 /PRNewswire/ -- DelveInsight's Heparin Market Insights report provides the current and forecast market analysis, individual leading heparin companies' market shares, challenges, heparin market drivers, barriers, trends, and key market heparin companies in the market. Key Takeaways from the Heparin Market Report As per DelveInsight estimates, North America is anticipated to dominate the global heparin market during the forecast period. In the application segment of the heparin market, the coronary artery disease category had a significant revenue share in the Heparin market in 2023. Notable heparin companies such as Pfizer Inc., Leo Pharma A/S, Dr. Reddy's Laboratories Ltd., GSK plc., Sanofi, B. Braun Melsungen AG, Aspen Holdings, Fresenius SE & Co. KGaA, Novartis AG, Baxter, and several others, are currently operating in the heparin market. In November 2023, the FDA approved a taurolidine plus heparin (DefenCath®) catheter lock solution to reduce catheter-related bloodstream infections in patients receiving maintenance hemodialysis via a central venous catheter (CVC). In February 2022, Techdow USA Inc. announced the launch of its Heparin Sodium Injection, USP in the US market. In January 2022, the Ohio biotechnology firm Optimvia Pharmaceuticals developed a cost-effective synthetic method to produce large quantities of heparin, used to make common blood thinner, also striking a deal with the synthetic biology firm Ginkgo Bioworks to scale the process up. To read more about the latest highlights related to the heparin market, get a snapshot of the key highlights entailed in the Global Heparin Market Report Heparin Overview Heparin is a widely used anticoagulant medication that helps prevent and treat blood clots. It works by enhancing the activity of antithrombin III, a protein in the blood that inhibits blood clotting factors such as thrombin and factor Xa. Heparin is administered either intravenously or subcutaneously and is commonly used in medical settings such as during surgeries, dialysis, and for patients with certain types of heart disease. Its rapid onset and short duration of action make it particularly useful in acute settings where quick and reversible anticoagulation is needed. Despite its effectiveness, heparin therapy requires careful monitoring due to the risk of bleeding complications. One of the most significant side effects is heparin-induced thrombocytopenia (HIT), a condition where the patient's platelet count drops dramatically, which paradoxically increases the risk of thrombosis. To manage these risks, healthcare providers regularly monitor blood clotting parameters, such as activated partial thromboplastin time (aPTT), to ensure that the patient remains within a therapeutic range. In cases where heparin use is contraindicated or needs to be discontinued, alternative anticoagulants, such as low molecular weight heparins or direct oral anticoagulants, may be considered. Heparin Market Insights In 2023, North America held the largest share of the heparin market compared to other regions. This is attributed to the rising incidence of cardiovascular disorders in the area. Contributing factors include the increasing risk factors related to cardiovascular issues, strong research and development efforts, and a highly promising market for product development and launches, all of which are driving the growth of the heparin market in North America. Additionally, the growing number of heparin product launches is anticipated to drive the heparin market in North America. For instance, in February 2024, B. Braun Medical Inc. introduced its new Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection, 1,000 mL (2 units/mL), marking the fifth addition to its range of Heparin premixed bags. This launch underscores B. Braun's dedication to enhancing supply security by producing pharmaceuticals in the U.S. at its Irvine, CA facility. Given the substantial patient population in North America, the use of heparin for treatment is expected to boost market demand in the coming years. Consequently, these factors combined are projected to contribute to the growth of the heparin market in North America during the forecast period from 2024 to 2030. To know more about why North America is leading the market growth in the heparin market, get a snapshot of the Heparin Market Outlook Heparin Market Dynamics The heparin market is a critical segment within the global pharmaceutical industry, primarily driven by its essential role in anticoagulant therapy. The market dynamics are influenced by a variety of factors including technological advancements, regulatory changes, and shifts in healthcare practices. One significant driver in the heparin market is the ongoing innovation in drug delivery systems and formulations. Advances such as low molecular weight heparins (LMWHs) have improved the efficacy and safety profiles of heparin therapy, leading to increased adoption. Additionally, the development of more efficient manufacturing processes, such as recombinant heparins, has helped meet the growing demand and reduce dependency on animal sources, which can be susceptible to supply chain disruptions. Regulatory factors also play a crucial role in shaping the heparin market. Regulatory agencies, such as the FDA and the EMA, impose stringent standards on the production and quality of heparin products. These regulations are designed to ensure the safety and efficacy of heparin, which can impact market dynamics through compliance costs and potential market entry barriers for new players. Moreover, market dynamics are influenced by global healthcare trends and economic factors. Rising incidences of cardiovascular diseases and an aging population contribute to the increased demand for heparin. However, economic pressures and healthcare cost containment strategies may impact market growth. Furthermore, competition from alternative anticoagulants and biosimilars can also affect the heparin market by offering patients and healthcare providers additional options. Get a sneak peek at the heparin market dynamics @ Heparin Market Dynamics Analysis Heparin Market Assessment Heparin Market Segmentation Heparin Market Segmentation By Source: Bovine, Porcine, and Others Heparin Market Segmentation By Route of Administration: Subcutaneous and Intravenous Heparin Market Segmentation By Application: Coronary Artery Disease, Atrial Fibrillation, Venous Thromboembolism, Renal Impairment, and Others Heparin Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the heparin market are set to emerge as the trendsetter explore @ Heparin Companies Table of Contents Interested in knowing the heparin market by 2030? Click to get a snapshot of the Heparin Market Trends Related Reports Heparin-induced Thrombocytopenia Market Heparin-induced Thrombocytopenia Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key heparin-induced thrombocytopenia companies, including Sandoz, Fresenius Kabi, Hikma Pharm, Veralox Therapeutics, among others. Thrombocytopenia Market Thrombocytopenia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key thrombocytopenia companies, including Sanofi, Principia Biopharma, Baxalta, Takeda, Argenx, Millennium Pharmaceuticals, Biotest, GC Pharma, Genosco (Subsidiary of Oscotec), Rigel Pharmaceuticals, Kissei Pharmaceutical, Shionogi & Co., Ltd, Amgen, Novartis, Zenyaku Kogyo, among others. Thrombocytopenia Pipeline Thrombocytopenia Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key thrombocytopenia companies, including Takeda, Argenx, Keros Therapeutics, Principia Biopharma, Momenta Pharmaceuticals, Veralox Therapeutics, Novartis Pharmaceuticals, Pfizer, HUTCHMED, Principia Biopharma, Genosco, UCB, among others. Immune Thrombocytopenia Immune Thrombocytopenia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key immune thrombocytopenia companies, including UCB Biopharma, Sanofi, Principia Biopharma, Argenx, Millennium Pharmaceuticals, Takeda, Biotest, GC Pharma, UCB, HanAll Biopharma, Immunovant, Momenta Pharmaceuticals, Hutchison MediPharma, Cour Pharmaceutical Development, among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP

Drug Approval

03 Sep 2024

·www.businesswire.com

Revolutionary Trial Aims to Transform Pancreatic Cancer Treatment

MARTINEZ, Calif.--( BUSINESS WIRE )--The first patient has been enrolled in ExThera Medical’s OSCAR I STUDY ( O NCObind C TC R emoval Study) clinical study at OU Health Stephenson Cancer Center, the clinical partner of the University of Oklahoma. The study is a Prospective Single-Arm Feasibility trial to evaluate the initial safety and signals of efficacy by determining the ability of the ONCObind procedure hemoperfusion filter to remove Circulating Tumor Cells (CTCs) from the blood of patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC). "The enrollment of the first patient in the OSCAR I STUDY is a significant milestone in our mission to provide innovative treatment options for cancer patients," said Erin Borger, CEO of ExThera Medical. "This trial represents the opportunity to offer potential new hope for patients with metastatic PDAC, who currently face limited options and poor prognosis.” The ONCObind procedure hemoperfusion filter is the product brand name for the Onco-Seraph platform that is an extracorporeal blood filtration procedure designed to target and filter out CTCs from the bloodstream of patients. CTCs are shed from primary tumors and contribute to metastasis, which is responsible for most cancer-related deaths. The ONCObind procedure uses a blood filter based on ExThera’s Seraph® 100 Microbind® Affinity Blood Filter technology, which has shown significant success in reducing CTCs in a recent in vitro study . The OSCAR I Trial is expected to enroll 5 patients with PDAC, followed by the OSCAR II feasibility trial. Pharmacokinetics/Pharmacodynamics will be the study focus of OSCAR I in the first 5 patients before expanding to additional participants. Patients will receive standard of care follow up for up to 5 years. This trial marks a significant first step toward FDA approval and commercialization of this cutting-edge treatment option. Further details on the OSCAR I study can be found here . About ExThera Medical Corporation ExThera Medical Corporation develops and commercializes extracorporeal blood filtration devices, including the Seraph® 100 Microbind ® Affinity Blood Filter for removing a broad range of pathogens from the bloodstream of patients. Seraph® 100 can be used in hospitals, clinics, on battlefields and in other austere environments to address nosocomial and community-acquired infections as well as those caused by battlefield wounds, pandemics, and biological warfare agents. ExThera Medical’s extracorporeal products have demonstrated life-saving capabilities in a wide range of critically ill patients suffering from sepsis, COVID-19, and many other severe bloodstream infections. With a growing body of outcome and health economic evidence from independent clinical studies, success in the DARPA Dialysis-Like Therapeutics program, and from successful clinical use in the US, the EU, and the Middle East, the company is well positioned to serve healthcare professionals and patients alike. The Seraph® 100 attained CE Mark and is commercially available in the EU under a broad Indication For Use. The Seraph® 100 has FDA Emergency Use Authorization (EUA) for treatment of COVID-19 in the USA. For more information, visit the company’s website at www.extheramedical.com . About Seraph® 100 and the ONCObind Procedure As a patient’s blood flows through the Seraph® 100 filter, it passes through a bed of small beads with receptors that mimic the receptors on human cells that pathogens target when they invade the body. Many harmful substances are quickly captured and adsorbed onto the surface of the beads and are thereby subtracted from the bloodstream. Seraph® adds nothing to the bloodstream. It targets the pathogens that cause the infection, while it also binds and removes harmful substances generated by the pathogen and by the body’s response to the infection. Seraph’s proprietary adsorption media (the beads) constitute a flexible platform that uses immobilized (chemically bonded) heparin for its well-established blood compatibility and its unique ability to bind circulating tumor cells, bacteria, viruses, fungi, and important sepsis mediators reported to contribute to organ failure during sepsis. ExThera Medical is currently developing the ONCObind™ Procedure Hemoperfusion Filter (ONCObind™) to support cancer treatment. ONCObind™ is part of the same platform technology as Seraph® 100. For more news stories on Seraph® 100 and ONCObind™, click here . Disclaimer All information contained in this news release derives from plausible, reliable sources which, however, have not been independently examined. There is no warranty, confirmation or guarantee, and no responsibility or liability is taken concerning correctness or completeness. As far as it is allowed by the relevant law, no liability whatsoever is taken on for any direct or indirect loss caused by the deployment of this news release or its contents. This communication includes forward-looking statements regarding events, trends and business prospects that may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. The investment and/or the revenues that arise from it can rise or fall. A total loss is possible. Persons who are in possession of this news release are requested to obtain information concerning possible legal limitations and to observe them accordingly. We assume no responsibility to update or revise any forward-looking statements contained in this news release to reflect events, trends, or circumstances after the date of this news release. Results from case studies (reviews) may not be predictive of future results.

Clinical Study

27 Aug 2024

·www.prnewswire.com

InsightRX Announces the release of InsightRX GEMINI(SM)

InsightRX GEMINI℠ is designed to save clinician time and eliminate the need for manual model filtering SAN FRANCISCO, Aug. 27, 2024 /PRNewswire/ -- InsightRX – the leader in Bayesian model-informed precision dosing software – today announced the release of InsightRX GEMINI℠. Privately released to select customers on July 30, 2024, this enhanced dose-selection algorithm for vancomycin was built from datasets of 384,000+ patient treatment courses. Clinical guidelines recommend dosing vancomycin based on area under the plasma drug concentration-time curve (AUC). AUC estimation accuracy is greatly dependent on the model and method used; which has been a time-consuming test and review process. In just one-click, InsightRX GEMINI℠ works by: Parsing out relevant patient data based on vancomycin's pharmacokinetics (PK) Making an initial PK model selection from InsightRX's validated catalog Accessing InsightRX's real-world data network to match the treatment patient to similar historical patients to compare PK model performance Summarizing and reviewing learnings to objectively select the best performing PK model to determine dosing InsightRX's new algorithm is based on experience and research, following seven years of applying model-informed precision dosing (MIPD) to treat over one million patients. InsightRX GEMINI℠ automates the selection of the most effective vancomycin PK model at the start of therapy, using patient characteristics known to impact model performance, like body mass index (BMI) and age. Auto-selected models can reduce bias, and result in better overall performance – ensuring a consistent best-practice standardization across healthcare systems. External validation of the algorithm in a separate dataset of 144,000 patients showed that following the InsightRX GEMINI℠ model selection increased model prediction accuracy by as much as 47% from baseline compared to a single-model approach. InsightRX set forth to develop an algorithm to select the best model for the widest range of individual patients based on 130+ patient characteristic combinations, which resulted in raising dosing prediction accuracy by 20-50% from previous iterations. This innovative algorithm is born from the collaborative power of InsightRX's seasoned data scientists and clinical pharmacy specialists, following in the footsteps of InsightRX's recent release of the first commercially available precision dosing model for heparin on the market. "Clinicians have been asking for a one-click application to select the best model to determine vancomycin dosing," said Sirj Goswami, Ph.D., InsightRX CEO and co-founder. "InsightRX GEMINI℠ removes the manual patient-factor selection process, making the dosing review process faster at point of care." Learn more about InsightRX GEMINI℠ at ASHP Midyear (Dec 8-12) in New Orleans where the InsightRX team will be showcasing their newest products and features helping to enhance the impact of precision dosing. About InsightRX InsightRX is a healthcare technology company providing a cloud-based clinical decision support platform that applies quantitative pharmacology and AI to enhance therapeutic decision-making from phase I drug development to point of care. The company's platform provides an individualized, predictive understanding of a patient's response to treatment which enables an enhanced understanding of dose-effect response and toxicity for clinicians to improve medication effectiveness. Media Contact Michelle Noteboom Amendola Communications for InsightRX [email protected] SOURCE InsightRX

100 Deals associated with Heparin Calcium

External Link

KEGG	Wiki	ATC	Drug Bank
D04427	Heparin Calcium	S01XA14 B01AB01 C05BA03	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Disease, Chronic Obstructive	Phase 2	GB	Ockham Biotech Ltd.	30 Jan 2022
Cystic Fibrosis	Phase 1	GB	Ockham Biotech Ltd.	30 Jan 2022
Asthma	Preclinical	GB	Ockham Biotech Ltd.	30 Jan 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ISN WCN2024	Not Applicable	-	18	Heparin	xraagygrgc(nedrojfnsl) = mfundyqcrs lgvrqgwegr (tvvwrxuezv ) View more	Positive	01 Apr 2024
				Kitelock™	vjwoecndhb(avvtymayqa) = aghnkiahpe wbxeumciuq (xiidmuzxsr ) View more
NCT02311231 (VALIDATE-SWEDEHEART, Pubmed) Manual	Phase 4	Non-St Elevated Myocardial Infarction \| ST Elevation Myocardial Infarction	6,006	Bivalirudin	(wdxnjcuzhw) = ysgvwycbte bgrebqlkjy (pmekiusfiu ) View more	Similar	26 Mar 2024
				Heparin	(wdxnjcuzhw) = fxxhjhlhcs bgrebqlkjy (pmekiusfiu ) View more
PERIOP-01 (ASH2023)	Not Applicable	Colorectal Cancer	614	Extended duration thromboprophylaxis with low-molecular-weight-heparin	(rnmwxsqnlh) = uyqjrfckyk fuxfznfmmv (oftfhqjrax ) View more	-	10 Dec 2023
				Standard duration thromboprophylaxis	(rnmwxsqnlh) = cqbdozjcbx fuxfznfmmv (oftfhqjrax ) View more
NCT04772209 (BicarbLock, Pubmed \| Int Urol Nephrol)	Not Applicable	Dialysis Access Failure	441	Heparin	ourlcdtuxr(kxogdhptob) = hdloouxjtc onfxmijwcs (zscublimok )	Positive	12 Oct 2023
				Sodium bicarbonate	ourlcdtuxr(kxogdhptob) = exeojjoexv onfxmijwcs (zscublimok )
VALIDATE-SWEDEHEART (ESC2023)	Not Applicable	ST Elevation Myocardial Infarction \| Non-St Elevated Myocardial Infarction	6,006	Bivalirudin	quqrbqhytk(kuocketukh) = xlqhpitqai xrlisdecdj (isixmmburi )	Negative	28 Aug 2023
				Heparin	quqrbqhytk(kuocketukh) = bzeqvearrd xrlisdecdj (isixmmburi )
ESC2023	Not Applicable	Venous Thromboembolism	-	Apixaban	(fzmzwlzrmr): HR = 0.42 (95% CI, 0.34 - 0.53) View more	-	28 Aug 2023
				Low-molecular weight heparin
ESC2023	Not Applicable	-	768	Heparin dose 50IU/kg	virqdpewza(vovzdeuaon) = lcoxeigvws wxwwgavras (ciypploxlo )	-	27 Aug 2023
				Heparin dose ≥70IU/kg	virqdpewza(vovzdeuaon) = wutgzcehtx wxwwgavras (ciypploxlo )
DEXHEP study (ISTH2023)	Not Applicable	PF4	165	Patients receiving unfractionated heparin with citrated tubes	zryhejhhbc(egacqrtsre) = puwqnttupu qvxzbvwofx (haybjbofeg, +301 - +406)	-	24 Jun 2023
ERA2023	Not Applicable	Hemodialysis complication	70	Trisodium citrate 30%	ctsyglulaa(pkjwjrdgdw) = xgucieewql clafzwfbxc (mlezcjjtwn ) View more	-	15 Jun 2023
				Unfractionated heparin	ctsyglulaa(pkjwjrdgdw) = fzlpntmrum clafzwfbxc (mlezcjjtwn ) View more
NCT03894904 (CTgov)	Phase 4	Anesthesia \| Vasospasm	100	Heparin+Papaverine (Papaverine Plus Heparin During Procedure, With Rescue Papaverine as Needed)	gfsntxffub(zamzjmrycr) = wwwftjsakw clelhwemlm (djetghlxqk, vvdutzswpn - csjguumyqe) View more	-	27 Oct 2022
				Heparin+Rescue papaverine, as needed (Heparin During Procedure, With Rescue Papaverine as Needed)	gfsntxffub(zamzjmrycr) = veimhytqdr clelhwemlm (djetghlxqk, ioalpnuuiq - ewstqlofqw) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis